A new article from Patient Power highlights findings from a paper authored by Ovarian Cancer Research Alliance (OCRA) and Komodo Health, that reveals significant gaps in genetic testing for ovarian cancer patients. Chad Ramsey, OCRA’s Vice President of Policy, spoke with Patient Power about the study’s results and the urgent need to close these gaps. … Continued
Spring is here—and so is appropriations season in Washington, DC. This month has brought key developments in both the FY26 federal budget process and state-level policy action that could impact gynecologic cancer research, prevention, and patient care. Here’s what advocates need to know: Draft Budget Proposal Would Eliminate Key CDC Cancer Programs A draft of the administration’s … Continued
Ovarian Cancer Research Alliance is proud to support five outstanding scientists through our Early Career Investigator Grants, part of the $6 million in new research OCRA is funding in 2025. These grants are essential to ensure that promising researchers with an established commitment to ovarian and related gynecologic cancers can continue to focus their efforts on … Continued
Ovarian Cancer Research Alliance hosted a free online seminar on April 9th titled “Endometrial Cancer: Understanding Biomarker Testing & Its Value in the Changing Treatment Landscape.” Dr. Ramez Eskander of UC San Diego Moores NCI-Designated Comprehensive Cancer Center and Dr. Ann Klopp of The University of Texas MD Anderson Cancer Center answered questions live, discussing … Continued
Ovarian Cancer Research Alliance’s Vice President of Policy, Chad Ramsey, spoke with Ellen Bryan of WUSA-TV’s Great Day Washington, and shared important new findings from a paper co-authored by OCRA and Komodo Health. The analysis reveals that nearly half of women diagnosed with ovarian cancer don’t receive essential genetic testing, despite its impact on treatment and … Continued
DISPARITIES IN TESTING RATES AMONG OLDER WOMEN AND THOSE ON PUBLIC INSURANCE PERSIST [New York, New York – March 25, 2025] – Nearly half of women diagnosed with ovarian cancer are not receiving the genetic testing that could help guide treatment and improve outcomes, according to a new analysis released today by Ovarian Cancer Research … Continued
Ovarian Cancer Research Alliance’s Vice President of Policy, Chad Ramsey, spoke with Ellen Bryan of WUSA-TV’s Great Day Washington ahead of OCRA’s Advocacy Day on March 25th. Ramsey shared new data from a paper co-authored by OCRA, to be released next week, which reveals that nearly half of diagnosed women don’t receive essential genetic testing, … Continued
OCRA is proud to announce the first three recipients of the $6 million we have awarded to support groundbreaking ovarian and related gynecologic cancer research in 2025. And we’re not stopping there—stay tuned as we continue to expand our investment in research this year. This is the first in a multi-part series introducing our newest … Continued
Rates of cervical precancer dropped nearly 80% between 2008 and 2022 among screened women aged 20 to 24, according to the latest Morbidity and Mortality Weekly Report from Centers for Disease Control and Prevention (CDC). The report notes that women in this age group are those most likely to have received the HPV vaccine. Read the … Continued
Join us Wednesday, April 9, 2025, for a FREE online seminar to learn about the importance of genetics and biomarkers on the treatment of endometrial cancer. This comprehensive program will cover essential topics including the difference between genetics and biomarkers, what tests are most effective in understanding treatment options, which testing is needed at diagnosis vs. recurrence, … Continued
New administrations inevitably bring changes, both big and small. The top priority of OCRA’s Policy & Advocacy team remains the same—ensuring the voices of the ovarian and gynecologic cancer community are heard and the issues that impact our community are considered. Next month, OCRA’s Advocate Leaders will convene in Washington, DC to once again bring … Continued
In a new article from TheaterMania, ovarian cancer survivor and OCRA Advocate Leader Kristen Jantonio shares how her passion for theater has been a source of strength and inspiration since being diagnosed with ovarian cancer. Through OCRA’s Advocate Leader program, she helps drive policy changes that support the gynecologic cancer community. Learn more in Playhouse Square’s Kristen … Continued
Get email updates about research news, action alerts, and ways to join the fight.
